ESMO Wrap, A Twitchy IPO Market, & Novartis Picks Microsoft for AI Help

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Gilead, Moderna Rise to the Occasion, Esperion Goes Back-to-Back, & Sangamo’s Big Neurology Deal
Lilly, Genentech Alzheimer’s Drugs Fail, Revolution’s Big IPO, & an Obesity Drug Disappears
Sanofi’s Intriguing MS Drug, Merck’s Big Spinoff & a New Peanut Allergy Drug
Wuhan Coronavirus Fear Spreads, CVS Feels the Heat & Black Diamond’s Sizzling IPO